Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Acceleration of RAD204 Phase 1 dose escalation trial

Monday, May 12, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has accelerated the Phase 1 dose escalation trial of RAD204, marking a significant step in its clinical development. The company has successfully dosed the first patient, which reflects its ongoing commitment to advancing innovative therapies. This progress is expected to enhance the company's position in the biopharma landscape.
Price reaction · baseline $4.18 (2025-05-09 close) · hit pre-market · 1 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acceleration of the RAD204 trial indicates progress in development.
  • First patient dosed in the trial shows commitment to clinical research.
  • Positive updates suggest strong potential for RAD204.

Full Press Release Details

• Announcements
• Price Sensitive
• May 12, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• September 13, 2024
• Announcements
• June 25, 2024
• Announcements
• March 7, 2025
• Announcements
• February 28, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the RAD204 trial about?

The RAD204 trial is a Phase 1 dose escalation study focused on evaluating the safety and efficacy of RAD204.

Who is conducting the RAD204 trial?

The trial is being conducted by Radiopharm Theranostics.

What recent progress has been made in the RAD204 trial?

The trial has accelerated, and the first patient has been dosed.

What does the acceleration of the trial signify?

It indicates significant progress in the clinical development of RAD204.

Tags: RADX Viatris Investor Conferences Healthcare RAD204 Phase 1 trial Radiopharm Theranostics clinical research
Last updated: May 12, 2025